There is great interest in stem cells because they have potential to replace defective or damaged cells resulting from a variety of disorders and injuries, leading to a range of new regenerative therapies. Stem cells also have value as a research tool, as their in vitro study would allow scientists to learn more about the function of various organs and the development of particular diseases; stem cells may also eventually permit drug developers to test emerging therapies on diseased cells.


For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the pharmaceutical market. New scientific developments and recent changes in the U.S. Federal government's policy towards stem cells have made this potential more relevant. Kalorama Information has tackled the question in Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development. Kalorama analyst Alison Sahoo has built models to determine the best, moderate and worst case scenarios for the three key markets for stem cells:
  • Stem Cells in Drug Development
  • Stem Cells in Cord Blood Banking
  • Stem Cell Therapeutics


Stem cell therapeutics potentials are provided, broken down by disease:

  • Cardiovascular disease

  • Lung disease

  • Tooth disease

  • Arthritis

  • Wrinkles/aging skin

  • Incontinence

  • Osteoporosis

  • Diabetes

  • Cancer

  • Bladder disease

  • Infertility

  • Orthopedics

  • Alzheimer’s disease

  • Burns (severe)

  • Lupus

  • Parkinson’s disease

  • Liver failure

  • Multiple sclerosis

  • Critical limb ischemia

  • Intestinal disease

  • Sickle cell disease

  • Multiple myeloma

  • NH Lymphoma

  • Leukemia


The following trends are discussed in this report:

  • Ethical Questions

  • U.S. – State and Federal Initiatives

  • Research Funding

  • Cord Blood Initiatives

  • International Initiatives

  • Stem Cell Patents

  • Other Healthcare Regulations
  • Table Of Contents

    CHAPTER ONE: EXECUTIVE SUMMARY

    Scope and Methodolgy

    Introduction

    Current Stem Cell Therapies

    Developmental Stem Cell Therapies

    Issues In Stem Cell Research

    Stem Cell Forecasts

    CHAPTER TWO: INTRODUCTION

    The Promise of Stem Cells In Medical Treatment

    Types of Stem Cells

    Embryonic Stem Cells

    Adult Stem Cells

    Cord Blood Stem Cells

    Stem Cell Harvesting

    Embryonic Stem Cells

    Therapeutic Cloning

    Unfertilized Eggs

    Adult Stem Cells

    Leukapheresis

    Peripheral Blood

    Cord Blood Stem Cells

    Transplantation Approaches

    Autologous Transplantation

    Allogenic Transplantation

    Transplantation Procedures

    Cancerous Stem Cells

    Other Harmful Stem Cells

    Stem Cells in Drug Development

    Stem Cell Therapeutics

    Stem Cells Targeting Drugs

    Stem Cell Generated Organs

    CHAPTER THREE: CURRENT STEM CELL THERAPIES

    Cancer

    Leukemia

    Gene Therapy

    Multiple Myeloma

    Non-Hodgkin’s Lymphoma

    Non Cancerous Diseases

    Aplastic anemia

    Immunodeficiency

    Lupus

    Sickle Cell Disease

    Other Conditions

    CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES

    Alzheimer’s Disease

    Arthritis

    Bladder Disease

    Burns

    Cancer

    Cardiovascular Conditions

    Critical Limb Ischemia

    Diabestes

    Esophagal Disease

    Incontinence

    Infertility

    Intestinal Disease

    Liver Failure

    Lung Disease

    Multiple Sclerosis

    Orthopedics

    Osteoporosis

    Parkinson’s Disease

    Sickle Cell Disease

    Tooth Disease

    Wrinkles/Aging Skin

    CHAPTER FIVE: STEM CELL FORECASTS

    Best Case

    Stem Cell Therapeutics

    Umbilical Cord Blood Banking

    Fees Related to Drug Development

    Most Likely Case

    Stem Cell Therapeutics

    Umbilical Cord Blood Banking

    Fees Related to Drug Development

    Worst Case

    Stem Cell Therapeutics

    Umbilical Cord Blood Banking

    Fees Related to Drug Development

    CHAPTER SIX: ISSUES IN STEM CELL RESEARCH

    Ethical Questions

    U.S. - State and Federal Initiatives

    Research Funding

    Federal Funding

    State Funding

    Cord Blood Initiatives

    International Initiatives

    Stem Cell Patents

    Other Healthcare Regulations




    LIST OF EXHIBITS




    CHAPTER ONE: EXECUTIVE SUMMARY

    Table 1-1 Total Market for Stem Cell Technologies in $ Millions, 2010 - 2020

    Table 1-2 Stem Cell Therapeutics Market in $ Millions, 2010 - 2020

    Table 1-3 Total Market for Cord Blood Banking Fees in $ Millions, 2010 - 2020

    Table 1-4 Total Market for Stem Cell Drug Development Technologies in $ Millions, 2010 - 2020

    Figure 1-1 Total Market for Stem Cells - Most Likely Case in $ Millions, 2010 - 2020

    CHAPTER TWO: INTRODUCTION

    Table 2-1 Established and Emerging Artificial Organ Products by Market Segment, 2010

    CHAPTER THREE: CURRENT STEM CELL THERAPIES

    Table 3-1 Types of Leukemia, 2011

    CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES

    Table 4-1 Global Disease Populations Addressed by Potential Stem Cell Therapies, 2011

    Table 4-2 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2010 and 2020

    Table 4-3 Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2010 and 2020

    Table 4-4 Features and Types of Urinary Incontinence, 2011

    Table 4-5 Types and Causes of Male Infertility, 2011

    Table 4-6 Common Diseases of the Lungs, 2011

    CHAPTER FIVE: STEM CELL FORECASTS

    Table 5-1 Persons Affected by Key Stem Cell Therapeutic Targets in Millions, 2011

    Table 5-2 Best Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 - 2020

    Table 5-3 Best Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 - 2020

    Table 5-4 131 Best Case: Cord Blood Banking Revenues in $ Millions, 2007 - 2020

    Table 5-5 Best Case: Stem Cell-Based Drug Development Technology Fees, 2010 - 2020

    Table 5-6 Best Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2010 - 2020

    Table 5-7 Most Likely Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 - 2020

    Table 5-8 Most Likely Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 - 2020

    Table 5-9 Most Likely Case: Cord Blood Banking Revenues in $ Millions, 2010 - 2020

    Table 5-10 Most Likely Case: Stem Cell-Based Drug Development Technology Fees in Millions, 2010 - 2020

    Table 5-11 Most Likely Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2010 - 2020

    Table 5-12 Worst Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 - 2020

    Table 5-13 Worst Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 - 2020

    Table 5-14 Worst Case: Cord Blood Banking Revenues in $ Millions, 2010-2020

    Table 5-15 Worst Case: Stem Cell-Based Drug Development Technology Fees in Millions, 2010-2020

    Table 5-16 Worst Case: Stem Cell-Based Drug Development Technology Fees in $ Millions 2010-2020

    CHAPTER SIX: ISSUES IN STEM CELL RESEARCH

    Table 6-1 NIH Funding for Stem Cell Research, 2002 - 2010 in $ Million

    Table 6-2 U.S. State Embryonic and Fetal Research Laws

    Table 6-3 Positions on Human ES Cell Research by Country, 2011

    Table 6-4 EU Laws on hESC Research by Country

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

3D Bioprinting 2014-2024: Applications, Markets, Players

3D Bioprinting 2014-2024: Applications, Markets, Players

  • $ 3 995
  • Industry report
  • April 2014
  • by IDTechEx Ltd

3D bioprinting constitutes a raft of technologies, commercial and not-yet commercial, which have the potential to significantly impact a number of major markets, including in vitro testing for more efficient ...

Plasma Etching: Market Analysis and Strategic Issues

Plasma Etching: Market Analysis and Strategic Issues

  • $ 2 495
  • Industry report
  • July 2014
  • by Information Network

The future needs in plasma etching will be for ever tighter control of process variability, higher selectivity and less damage. This report addresses the strategic issues impacting both the user and supplie ...

Kidney Transplantation - Pipeline Review, H1 2014

Kidney Transplantation - Pipeline Review, H1 2014

  • $ 2 000
  • Industry report
  • March 2014
  • by Global Markets Direct

Kidney Transplantation - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Kidney Transplantation - Pipeline Review, H1 2014', provides an overview of the Kidney Transplantation's therapeutic ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.